$IMVT
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Healthcare
Sector
Biotechnology
Industry
Eric Venker
CEO
362
Employees
$38.85
Current Price
$5.42B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | All Sells |
| Sells | 5 | 8 | $3,335,415.72 | 87,038 | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 5 | 9 | $3,428,632.98 | 89,672 | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 5 | 10 | $3,479,662.98 | 91,172 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 6 | 16 | $11,210,846.57 | 322,238 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 7 | 23 | $12,719,802.36 | 377,273 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
4 more earnings records available โ create a free account to see 12 months of history